OncLive® On Air

Highlights from the PER® CME activity "Medical Crossfire®: Precision Oncology in NSCLC – Translating HER2 and TROP2 Innovation into Practice-Changing Care" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.

In this podcast, focusing on precision oncology in non-small cell lung cancer (NSCLC), experts Helena Yu, MD; Jacob Sands, MD; and Sarah Goldberg MD, MPH; will discuss the rapidly evolving landscape of Human Epidermal growth factor Receptor 2 (HER2)- and Trophoblast cell-surface antigen 2 (TROP2)-directed therapies in NSCLC. The podcast covers the spectrum of targeted agents from antibody-drug conjugates (ADCs) to novel HER2-selective tyrosine kinase inhibitors (TKIs), along with key clinical trial data and practical strategies for managing the unique adverse event profiles associated with these treatments.

Earn CME credit by completing the full accredited activity (available through June 30, 2027): https://www.gotoper.com/courses/medical-crossfire-precision-oncology-in-nsclc-translating-her2-and-trop2-innovation-into-practice-changing-care-mr5q

This podcast, including the narration, was developed by PER® (Physicians’ Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by educational grants from AstraZeneca Pharmaceuticals; Daiichi Sankyo, Inc.; and Gilead Sciences, Inc.

This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.

In today’s episode, we welcomed Charles E. Geyer, MD, to discuss recent FDA approvals of fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) for the management of HER2-positive breast cancer. Dr Geyer is a professor of medicine and chief of Malignant Hematology and Medical Oncology in the Department of Medicine at the University of Pittsburgh and the University of Pittsburgh Medical Center Hillman Cancer Center in Pennsylvania.

On May 15, 2026, the FDA approved T-DXd for the neoadjuvant treatment of adult patients with HER2-positive stage II or III breast cancer, as determined by an FDA-authorized test, followed by a taxane, trastuzumab (Herceptin), and pertuzumab (Perjeta); the regulatory agency simultaneously approved post-neoadjuvant T-DXd for the treatment of adult patients with HER2-positive breast cancer who have residual invasive disease after neoadjuvant HER2-targeted treatment.

In our exclusive interview, Dr Geyer discussed the significance of these approvals, key data from the pivotal trials, and how these new indications for T-DXd are shaking up the HER2-positive breast cancer treatment paradigm.

In today’s episode, we spoke with Martin Schoen, MD, and Andrew W. Hahn, MD. Dr Schoen is a hematologist/oncologist and hospitalist at St. Louis Veterans Affairs Medical Center and Assistant Professor of Medicine at Saint Louis University. Hahn is an assistant professor in the Department of Genitourinary Medical Oncology at The University of Texas MD Anderson Cancer Center.

In our exclusive interview, Drs Schoen and Hahn discussed the clinical evidence for androgen receptor pathway inhibitors (ARPIs), including enzalutamide, in patients with de novo metastatic castration-sensitive prostate cancer (mCSPC) who are elderly, frail, or have a high comorbidity burden. They also highlighted findings from a subgroup analysis the Veterans Affairs dataset evaluating outcomes with androgen deprivation therapy plus ARPIs in high-comorbidity, frail, and elderly patients with high-volume mCSPC.

In today’s episode, we welcomed Claire Harrison, MD, a professor of myeloproliferative neoplasms and clinical director at Guy's and St Thomas' NHS Foundation Trust in London, United Kingdom.

In the exclusive interview, Dr Harrison discussed management strategies for anemia in patients with myelofibrosis and the implications of the phase 3 INDEPENDENCE trial (NCT04717414) presented at the 2026 EHA Congress. Dr Harrison detailed the prevalence and current challenges in managing myelofibrosis-associated anemia. She also detailed key efficacy outcomes reported for luspatercept-aamt (Reblozyl) in the INDEPENCENCE study, along with outlining some of the factors that contributed to the study narrowly missing statistical significance for its primary end point of red blood cell transfusion independence for at least 12 consecutive weeks during the first 24 weeks of treatment.

Highlights from the PER® CME activity "Medical Crossfire®: Turning Therapeutic Innovation Into Practice—Personalizing Care in Multiple Myeloma" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.

In this podcast, experts Philippe Moreau, MD; Suzanne Lentzsch, MD, PhD; and Shaji Kumar, MD, discuss therapeutic innovations in the treatment of multiple myeloma, including frontline quadruplet therapy, administration considerations for therapy, and optimal sequencing of CAR T-cell therapy, bispecific antibodies, and antibody-drug conjugates.

Earn CME credit by completing the full accredited activity (available through June 5, 2027):
https://www.gotoper.com/courses/medical-crossfire-turning-therapeutic-innovation-into-practicepersonalizing-care-in-multiple-myeloma-p2f5

This podcast, including the narration, was developed by PER® (Physicians’ Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by an educational grant from Sanofi.

This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.

In today’s episode, we spoke with David O’Malley, MD. Dr O’Malley is a professor in the Department of Obstetrics and Gynecology at The Ohio State University College of Medicine and the director of the Division of Gynecologic Oncology at The Ohio State University Comprehensive Cancer Center–James in Columbus, Ohio. 

In our exclusive interview, Dr O’Malley discussed his approach to treatment selection and sequencing in platinum-resistant ovarian cancer, a disease setting he described as representing the highest unmet need in the field. He emphasized the central role of clinical trial enrollment and biomarker-driven decision-making, alongside practical patient-centered considerations, such as infusion schedule and quality of life.

He highlighted the growing importance of antibody-drug conjugates (ADCs) in this setting, noting that folate receptor alpha and HER2 are the two biomarkers most relevant to current practice. Dr O’Malley outlined how National Comprehensive Cancer Network guidelines support treatment across a broader range of expression levels than initial approvals reflected, citing emerging data suggesting activity even at lower expression thresholds. He also addressed payload sequencing, explaining that outside of a clinical trial, he currently uses topoisomerase I–based ADCs and antimicrotubule-based ADCs each one time only, and remains open to targeting the same antigen again if the payload differs.

The discussion also touched on combination strategies, resistance biology, and the evolving role of immunotherapy following the survival benefit observed with pembrolizumab (Keytruda) in the phase 3 KEYNOTE-B96 trial (NCT05116189). Dr O’Malley expressed enthusiasm for next-generation payloads, dual-target approaches, and the potential for bispecific antibodies and novel DNA damage response–targeting agents to define the post-ADC treatment landscape.

Finally, Dr O’Malley underscored the need for more tumor biopsies to better characterize resistance mechanisms and called for expanded pharmaceutical investment in retreatment and cross-resistance studies to guide future sequencing decisions.

In today’s episode, we spoke with Courtney D. DiNardo, MD, MSCE, a professor in the Department of Leukemia in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center and an associate member of The University of Texas Graduate School of Biomedical Sciences in Houston.

In our exclusive interview, Dr DiNardo discussed the May 2026 FDA approval of decitabine (Dacogen) and cedazuridine (Inqovi) plus venetoclax (Venclexta) in patients with newly diagnosed acute myeloid leukemia (AML). DiNardo outlined numerous important facets of the approval, including its effects on the treatment paradigm, which patients will benefit most, safety considerations with the regimen, and quality of life advantages that have been observed with the combination. Furthermore, she discussed how this approval fits into a larger shift for the AML treatment paradigm and how the AML research field can build upon the approval of this regimen.

Highlights from the PER® CME activity "Live Tumor Board: Translating Biomarker Insights and Therapeutic Advances Into Endometrial Cancer Practice" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.

In this podcast, experts Kathleen N. Moore, MD, MS, FASCO; Ritu Salani, MD, MBA; Casey Cosgrove, MD; and Ebony R. Hoskins, MD, FACOG, discuss several cases of endometrial cancer using biomarkers to drive treatment decisions.

Earn CME credit by completing the full accredited activity (available through June 26, 2027):
https://www.gotoper.com/iog26endometrial-activity

This podcast, including the narration, was developed by PER® (Physicians’ Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by educational grants from BioNTech; Eisai, Inc.

This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.

In this episode of Oncology Unplugged, host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, was joined by Muhamed Baljevic, MD, FACP, an associate professor of medicine in the Division of Hematology Oncology in the Department of Medicine at the Vanderbilt-Ingram Medical Center; as well as the director of the Multiple Myeloma Program and the Vanderbilt Amyloidosis Multidisciplinary Program and co-chair of the Protocol Review and Monitoring System at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee.

Their conversation focused on the rapid evolution of the multiple myeloma treatment paradigm, including the integration of quadruplet therapies, the clinical emergence of bispecific antibodies and CAR T-cell therapies, and the management of treatment-related toxicities. Drs Park and Baljevic examined data regarding quadruplet regimens, which are now the standard of care for transplant-eligible patients. They highlighted trial findings showing that patients with sustained minimal residual disease (MRD) negativity could successfully de-escalate maintenance therapy.

For relapsed disease, they discussed clinical trials investigating teclistamab, noting the agent's robust efficacy in the early-relapsed setting and among patients who have been previously refractory to CD38-targeted antibodies. The experts also discussed individualizing treatment through target switching and sequencing CAR T-cell therapy before bispecific antibodies to optimize T-cell health. To manage cytokine release syndrome, they recommended tocilizumab prophylaxis or the use of dexamethasone. Furthermore, Dr Baljevic highlighted the use of “flat-dose” intravenous immunoglobulin to mitigate infection risks, which maintains safety and significantly reduces financial toxicity and resource strain compared with weight-based dosing.

Regarding cellular therapies, the experts reaffirmed the potential for functional cures even in heavily pretreated patients. They also spotlighted the use of MRD status to stratify transplant-eligible patients to undergo autologous stem cell transplant vs T-cell redirection consolidation therapy.

Drs Park and Baljevic concluded by discussing MRD-informed treatment cessation. Dr Baljevic indicated that patients with standard-risk disease with 5 years of sustained MRD negativity could consider stopping maintenance therapy, but emphasized that patients with high-risk disease still require continuous treatment.